Biohaven Ltd.
BHVN
$14.71
-$0.39-2.58%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 24.60% | 18.84% | 36.80% | 30.52% | 90.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.91% | 16.47% | 61.17% | 255.04% | 135.58% |
| Operating Income | -20.91% | -16.47% | -61.17% | -255.04% | -135.58% |
| Income Before Tax | -23.55% | -27.97% | -51.48% | -262.48% | -157.26% |
| Income Tax Expenses | 7.03% | 103.96% | 98.21% | -91.87% | -39.40% |
| Earnings from Continuing Operations | -23.49% | -29.07% | -56.28% | -253.94% | -154.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.49% | -29.07% | -56.28% | -253.94% | -154.64% |
| EBIT | -20.91% | -16.47% | -61.17% | -255.04% | -135.58% |
| EBITDA | -20.64% | -16.30% | -61.61% | -259.97% | -138.78% |
| EPS Basic | 1.15% | -2.09% | -13.13% | -175.22% | -112.85% |
| Normalized Basic EPS | 1.59% | 5.02% | -9.62% | -173.86% | -107.94% |
| EPS Diluted | 1.15% | -2.09% | -13.13% | -175.22% | -112.85% |
| Normalized Diluted EPS | 1.59% | 5.02% | -9.62% | -173.86% | -107.94% |
| Average Basic Shares Outstanding | 24.93% | 26.43% | 38.13% | 28.60% | 19.64% |
| Average Diluted Shares Outstanding | 24.93% | 26.43% | 38.13% | 28.60% | 19.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |